Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-16
    E.g., 2018-10-16

Archive Search

6 results
4:25 PM, Oct 03, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

by Novartis AG could include testing the compound in additional animal models of bacterial infection. A2A Pharmaceuticals LLC
1:23 PM, Jul 20, 2018  |  BC Week In Review | Company News  |  Deals

Insilico, A2A launch Consortium.AI to develop candidates for rare orphan diseases

Insilico Medicine Inc. (Baltimore, Md.) and A2A Pharmaceuticals LLC (Chappaqua, N.Y.) partnered to launch Consortium.AI, a company that …
City run by the Johnson & Johnson Innovation LLC subsidiary of Johnson & Johnson (NYSE:JNJ). A2A Pharmaceuticals LLC
3:11 PM, Jun 01, 2018  |  BioCentury | Emerging Company Profile

Scratching the surface

its platform to develop molecules with bactericidal activity against Gram-negative bacteria. At least two companies, A2A Pharmaceuticals LLC
199,851) Investors: Undisclosed angel investors CEO: Ajay Mistry Patents: None issued Companies and Institutions Mentioned  A2A Pharmaceuticals LLC
9:20 AM, Jun 20, 2017  |  BC Innovations | Distillery Therapeutics

Infectious disease

AG could include testing the safety and PK/PD of the compound in the infection models. A2A Pharmaceuticals LLC
6:01 PM, Apr 27, 2017  |  BC Innovations | Finance

1Q17 public-private partnership roundup

the end of 2019. At least two other companies have LpxC inhibitors in preclinical development: A2A Pharmaceuticals LLC
has licensed the synthetic pox virus from the University of Alberta. Companies and Institutions Mentioned  A2A Pharmaceuticals LLC
12:00 AM, Aug 22, 2016  |  BioCentury | Emerging Company Profile

Metal smithing

hours in a mouse model of wild-type E. coli infection. At least one other company, A2A Pharmaceuticals LLC
its own IP covering the LpxC program and its cancer programs. Companies and Institutions Mentioned A2A Pharmaceuticals LLC